RxDoctor Payments Data

Shanan Munoz, MD

Neurology · Dallas, TXNPI 1528075132

Payments from drug & device makers

$383,405in general payments, 2019–2025

Across 196 payments — averaging $1956.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Products Limited$99K
  • Chugai Pharmaceutical Co., Ltd.$88K
  • Hoffmann-la Roche Limited$86K
  • F. Hoffmann-la Roche AG$23K
  • Biogen$18K
  • EMD Serono, Inc.$14K
  • plus $54K from 8 others

What the payments were for

  • Consulting fees$55,68474%
  • Speaking & faculty fees$6,2708%
  • Travel & lodging$7,0099%
  • Food & beverage$5,8568%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383,405 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$62,613
Medicare patients
310
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab164$1,655,283
CopaxoneGlatiramer Acetate45$263,600
EnspryngSatralizumab-Mwge12$182,288
Teriflunomide39$137,336
Avonex (4 Pack)Interferon Beta-1a12$85,796
GlatopaGlatiramer Acetate24$77,624
Dimethyl Fumarate73$68,470
Glatiramer Acetate30$61,688
Nurtec OdtRimegepant Sulfate27$54,933
LamictalLamotrigine19$48,328
KeppraLevetiracetam19$40,024
FingolimodFingolimod Hcl22$38,386
Dalfampridine ErDalfampridine32$12,884
VyvanseLisdexamfetamine Dimesylate23$8,824
Modafinil73$8,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Enspryng$12,858$182,28812 claims
BiogenAvonex (4 Pack)$18,269$85,79612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →